Some lots of irbesartan being recalled due to contamination with suspected carcinogen
THURSDAY, Nov. 1, 2018 (HealthDay News) — Another hypertension drug is being recalled due to contamination that could pose a cancer risk, the U.S. Food and Drug Administration says.
Certain lots of irbesartan are being recalled by SciGen because they contain an industrial chemical that is a suspected carcinogen, CNN reported. The recalled drugs have “Westminster Pharmaceuticals” and “GSMS Inc.” on the label.
Another heart drug, valsartan, was recalled recently due to contamination with possible cancer-causing chemicals, CNN reported.
Not all medicines that contain valsartan or irbesartan are being recalled. The new recall covers only about 1 percent of irbesartan drug products available in the United States, according to the FDA.
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians 
Antenatal Complications Increased With Maternal Multiple Long-Term Conditions 
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status 
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA 
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis 
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis 
Achieving Low Serum Urate Levels Can Cut Risk for Cardiovascular Events in Gout 
